Chiang Mai University

牢记嘱托 感恩奋进 登高望远 乘势而上 时序轮替，岁物丰成 2024年，我们感恩奋进，乘势而上 力促特色发展、内涵发展、卓越发展 谱写育人链与创药链互融共促的华章 2025年，我们携手并肩，开拓创新 续写闪“药”星辰的时代新篇 值此新年到来之际 浙江大学药学院 向全体师生 和关心支持学院发展的校友 企业和社会各界朋友 致以最美好的新年祝福 恭祝大家 新年快乐！喜乐安宁！ 让我们 一起回顾药苑十大热点新闻 共忆2024年的小美满 01 新闻一：药理毒理研究所教工党支部入选全国党建工作样板支部 - HAPPY NEW YEAR  - 4月16日，教育部公布了第四批全国党建“双创”工作培育创建单位名单，浙江大学4个基层党组织成功入选。其中，药学院药理毒理研究所教工党支部入选“全国党建工作样板支部”。 这一年，学院坚持高质量党建引领和保障高质量发展，努力在强国建设中发挥战略作用。学院师生深入学习宣传贯彻党的二十届三中全会精神和全国教育大会精神、全国科技大会精神，扎实开展党纪学习教育，将深学细悟习近平总书记关于全面加强党的纪律建设的重要论述贯穿始终，深化以案促学促改促治，进一步增强政治定力、纪律定力、道德定力、抵腐定力。加快推进基层党支部打造“四个共同体”，作为先行示范的典型样板开展主题突出、重点聚焦、内容充实、特色鲜明的本科教育教学质量提升大讨论主题党日活动，药理毒理研究所教工党支部入选全国党建工作样板支部、全省双带头人强国行专项行动，发展1名专任教师入党。 02 新闻二：祝贺！4项成果获浙江省科学技术奖 - HAPPY NEW YEAR  - 11月22日，加快建设创新浙江因地制宜发展新质生产力动员部署会暨全省科学技术奖励大会在杭州举行，会上表彰了2023年度浙江省科学技术奖。浙江大学药学院牵头获得浙江省自然科学奖一等奖2项、科学技术进步奖三等奖1项，参与获得浙江省科学技术进步奖一等奖1项。 这一年，学院聚焦国家重大战略需求，一体推进科技、教育、人才事业发展。科研团队在抗脑卒中药物发现、抗肝细胞癌新靶点发现、血液恶性肿瘤药物研发、抗前列腺癌候选药物、智能药物递释系统、组分中药智能创制等方面研究取得重要进展，发明贴敷式大剂量药物输注贴，建立首个药物作用下的细胞线粒体动态表型大规模数据集，发现去泛素化酶抗肿瘤新策略，2项抗肿瘤新药申请临床批件，3项原创制剂进入临床试验。教师获国家自然科学奖二等奖1项、国家科技进步奖二等奖1项，省级科技奖励4项；到位科研经费连续3年突破2亿元；持续高水平建设2个全国重点实验室，新增共建“全省抗肿瘤药物临床前研究重点实验室”等5个省重点实验室；中药制药工程学入选省中医药重点学科建设项目，实现各二级学科均衡发展、建立群峰竞秀学科生态。 03 新闻三：学生团队在中国国际大学生创新大赛（2024）中斩获一金两银！ - HAPPY NEW YEAR  - 10月15日，浙江大学药学院三支学生团队带项目成果：FlyDrug——全球新药发现智能化引领者、智联生物——大数据与AI赋能的差异化偶联药物发现先锋和神农“智”造——药食同源大健康产品研发革新参加中国国际大学生创新大赛，表现出色斩获一金两银，取得历史新突破。 这一年，学院始终坚持以学生成长为中心，深入实践育人链和创药链的双链融合，高质量加快构建有全球竞争力的药学拔尖创新人才培养体系。育人成果出色，获竺可桢奖学金2人，十佳大学生荣誉称号1人。药学学子在各类赛事中也展现风采：荣获第十四届“挑战杯”秦创原中国大学生创业计划竞赛金奖1项，中国国际大学生创新大赛（2024）金奖1项、银奖2项，“华为杯”第六届中国研究生人工智能创新大赛一等奖1项、省级双创赛事金奖6项，全国医药院校药学/中药学专业大学生实验技能比赛一等奖2项，全国大学生药苑论坛一等奖和优秀论文奖1人，浙江省大学生药学大赛银奖1项等多项全国和省部级奖项。 04 新闻四：导师成果获评8项全国药学专业学位研究生精品课程及优秀教学案例 - HAPPY NEW YEAR  - 近日，2024年全国药学专业学位研究生教育学术年会暨首届全国药学博士专业学位研究生教育发展研讨会在广州召开。会议举行了2024年全国药学专业学位研究生精品课程和第七届全国药学专业学位优秀教学案例颁奖仪式。浙江大学药学院荣获4项精品课程和4项优秀教学案例。 这一年，学院积极构建多元化、开放式的人力资源体系，营造群贤毕至的人才生态。持续实施“青蓝弘药”结对计划，开展“青蓝传承”系列讲座分享会，营造“青出于蓝、薪火相传”的药学特色文化；举办第五届“启真湖”国际青年药学人讲坛，吸引海外青年人才加盟；通过“药学强师”、青椒会专题研讨会等活动，支持教师持续成长；打通学院教师与校内外单位兼聘通道，促进学科交叉。师资中高层次人才比例显著提升，新增国家级人才2人、求是特聘教授2人，国家级青年人才4人。 05 新闻五：闪“药”青春遇见你！2024届学生毕业典礼举行 - HAPPY NEW YEAR  - 6月18日下午，浙江大学药学院2024届学生毕业典礼在紫金港校区剧场举行。261名本科生和研究生圆满完成学业，即将奔赴属于自己的锦绣前程。他们怀揣着对未来的期许，有的进入国内外顶尖高校深造，有的选择扎根基层奉献乡村建设，有的继续攀登新药研发的科研高峰。 这一年，学院聚集质量提升，加快培养药学拔尖人才。教育部基础学科拔尖人才培养计划2.0基地建设成效显著，获批全国首批药学博士专业学位授权点，开展药学学位授权点自我评估阶段工作，与中国科学院、中国中医科学院四个研究所签订人才培养实践基地。教学成果突出：推荐国家级一流课程3门，国家级规划教材1部，省四新教材重点教材立项3部，主编出版“十四五”研究生规划教材1部；新增全国教指委及省级教学改革成果及荣誉30余项、校级20余项。本科生深造率稳步提升，研究生教育质量持续提升，学生在实践创新中不断成长：本科生获批国家自然科学基金青年学生基础研究项目1项、博士生3项，获评浙江省优秀博士、硕士学位论文4篇。 06 新闻六：央视《新闻联播》报道 | 浙江大学智能创新药物研究院亮相 - HAPPY NEW YEAR  - 3月26日，央视《新闻联播》报道，浙江通过改革创新，为科研工作者量身打造多个公共服务平台，进一步释放科技成果转化活力，催化形成新质生产力。浙江大学智能创新药物研究院亮相。 这一年，学院响应时代号召，强化创新驱动，围绕新质生产力培育加快科技成果转化。以校地研究院为主平台，加快打造具有强大策源力的创新尖峰，新建1个院企联合研究平台，浙江大学金华研究院牵头获批全省智能新药创制重点实验室重组共建，并获批国家自然科学基金依托单位；浙江大学智能创新药物研究院持续强化杭州市概念验证中心的能力建设，推动促进科技成果转移转化；组织10余次多学科团队服务企业活动，先后走访太极集团、鲁抗医药等上市企业，并与金华、台州、菏泽等区域企业密切对接。师生“致远计划”实践团赴柬埔寨进行访问和交流，为当地医院和药企提供了技术支持，相关活动受到柬埔寨当地主流媒体报道。 07 新闻七：“黄鸣龙/黄鸣驹”弘药讲坛精彩纷呈 - HAPPY NEW YEAR  - 7月15日，“黄鸣龙/黄鸣驹”弘药讲坛第十二期在紫金港校区举行。特邀嘉宾美国德州大学奥斯汀分校Nicholas Peppas院士为师生带来精彩学术报告。Peppas院士是生物材料和制剂领域的国际顶尖学者，是中国工程院外籍院士，美国国家工程院院士、美国国家医学院院士、美国艺术与科学院院士等。Peppas院士以麻省理工学院的趣闻为引出，讲述了自身基于传统化工材料的研究向生物材料与药物制剂发现的探索和开拓,给师生以深刻启发。 这一年，学院大力弘扬科学家精神和教育家精神，赓续“求是创新”和“明德弘药”的精神血脉，促进新药源头创新与临床转化。邀请美国德州大学奥斯汀分校Ehud Gazit, 以色列特拉维夫大学Jonathan Sessler，美国德州大学奥斯汀分校Nicholas Peppas，西班牙圣地亚哥·德孔波斯代拉大学Maria Alonso，新加坡国立大学Xiaoyuan Chen等5位院士开设“黄鸣龙/黄鸣驹”弘药讲坛，邀请北京大学、西湖大学、南京大学、中国科学院上海药物所、京都大学、加州大学等42位专家教授开展“明德弘药”系列学术讲座和交流，一场场精彩纷呈的学术盛宴带来思想的碰撞。 08 新闻八：【药】你来浙里—首次举办SDG全球暑期学校药学模块 - HAPPY NEW YEAR  - 7月22日，2024年浙江大学可持续发展全球暑期学校（Zhejiang University 2024 SDG Global Summer School，简称SDG）药学模块Human Health: Advanced in Basic Research and Application首次举行，项目为期2周。22位来自全球的青年学子参加该项目，通过丰富的课程学习、实践参访和文化交流等活动，深入了解学习药学基础知识和应用。 这一年，学院持续深化国际交流与合作，打造全球开放发展新格局。与海外药学院校签署合作协议3份；积极鼓励师生走出去，与悉尼大学、奥克兰大学、清迈大学等开展互访交流，开展与日本岐阜药科大学合作交流40周年系列学术活动，在药物制剂与粒子设计、天然产物化学及化学生物学和人工智能与医药健康的交叉研究等领域举办具有行业和全球影响力的国际会议3场次；深化与美国哈佛大学、UNC、新加坡国立大学等海外顶尖药学高校合作、打造院级全球学习项目8项，增强在地国际化体验、首次SDG药学暑期学校和Grips项目、开设全英文课程6门；面向全球讲述药学故事，打造“我药看世界”专栏、全球学习vlog等一批高质量宣传品，英文网站访问量翻倍。 09 新闻九：举行1976届-2006届校友班级联络员会议 - HAPPY NEW YEAR  - 5月26日，，为进一步加强校友联系，充分发挥班级联络员作用，浙江大学药学院举行第二期校友班级联络员会议（1976届-2006届）。校友班级联络员围绕“学院服务校友、校友支持学院发展”主题召开座谈交流会。大家畅谈在校期间的学习体验和感受，同时为学院发展建言献策。 这一年，学院坚持“以服务求发展，用贡献创辉煌”，用心用情服务校友，群策群力保障发展。新聘任5位院士成为学院发展委员会委员；组织召开第二期班级联络员会议，搭建沟通桥梁、倾听校友声音；推进在杭校友成立杭州浙江大学校友会药学院分会，组织开展90级、00级、04级校友值年返校聚会活动，制作《校友通讯》，凝聚校友情谊、定格欢乐瞬间；策划校友系列专题报道，讲述身边故事、弘扬榜样力量；不断拓资源、做增量，年度签署捐赠协议27份，广大校友关心助力母校发展的热情持续高涨，为学院高质量发展更加稳健、更可持续、更有质效打下坚实基础。 10 新闻十：浙江大学药学院邀你共赏美好春光！ - HAPPY NEW YEAR  - 3月27日，校园内樱花绽放，临近药学院的樱花林春意盎然，满园桃红，吸引无数师生。 这一年，学院聚集师生为本，对内汇聚药学力量，对外打造浙药名片。在院内选树先进典型，强化示范引领，开展“明德弘药”年度人物、科技亮点工作、“闪药之星”十佳大学生评选；凝心聚力，增强师生归属感，举办“青春正好 荣药年华”毕业典礼、2025年新年晚会暨年度学生表彰大会；依托学科，传承科普药学文化，打造“紫金炊烟 传药百年”药膳大赛、神农百草园劳动实践，走进中小学决明科普小课堂等文化品牌活动。对外打造全方位宣传矩阵，向社会讲述药学故事，科技创新赋能医药行业高质量发展、地方研究院服务区域地方经济发展等药闻热点登上《人民日报》《央视新闻》《新华网》《钱江晚报》等主流媒体。 图文供稿｜徐潇 审核｜杨慧蓉 点击名片，关注我们

A new test diagnoses patients with melioidosis within hours, rather than days, meaning they can receive the correct antibiotics faster. Globally, more than half of patients die after infection with the neglected tropical disease, melioidosis, often before they are diagnosed. A new rapid test could save lives by diagnosing patients in hours, rather than several days taken by current bacterial culture methods, meaning they receive the correct antibiotics faster. The test uses CRISPR to detect a genetic target that is specific to Burkholderia pseudomallei, the bacterium that causes melioidosis, with 93 per cent sensitivity. It was developed by researchers at the Mahidol-Oxford Tropical Medicine Research Unit (MORU), Chiang Mai University, Vidyasirimedhi Institute of Science and Technology (VISTEC) in Thailand, and the Wellcome Sanger Institute in the UK. The results, published today (14 March) in Lancet Microbe, mean more lives could be saved from melioidosis, with a rapid, easy-to-use diagnostic test that could be rolled out globally. Melioidosis is a neglected tropical disease that is estimated to affect 165,000 people worldwide each year, of whom 89,000 die from the disease. It is caused by the bacterium, Burkholderia pseudomallei, which lives in soil and water in tropical and subtropical regions, and enters human bodies via inoculation through skin abrasions, ingestion or inhalation. It is difficult to diagnose melioidosis as symptoms vary from localised abscess or pneumonia to acute septicaemia, or may present as a chronic infection. As a result of this, and the locations of isolated communities in rural areas that it mostly affects, the disease remains hugely underreported. Currently, melioidosis is diagnosed in patients after bacterial samples are cultured, which takes three to four days. In Thailand, approximately 40 per cent of patients with melioidosis die, many of whom die within the first one to two days following admission to hospital, while waiting for a diagnosis. There is no licensed vaccine for melioidosis, but patients can be effectively treated with intravenous antibiotics -- ceftazidime or carbapenem -- during the first intensive phase of treatment. However, current practices often involve initially treating patients with a range of unnecessary antibiotics to target the various symptoms the disease produces, which can waste time and resources. In a new study, the team set out to develop a new rapid test to reduce the time taken to correctly diagnose and treat patients with melioidosis. The researchers identified a genetic target specific to B. pseudomallei byanalysing over 3,000 B. pseudomallei genomes, most of which were sequenced at the Sanger Institute. They searched for conserved regions of the genome and screened the targets against other pathogens and human host genomes, to ensure their chosen target was specific to B. pseudomallei. Their test, called CRISPR-BP34, involves rupturing bacterial cells and using a recombinase polymerase amplification reaction to amplify the bacterial target DNA for increased sensitivity. Additionally, a CRISPR reaction is used to provide specificity, and a simple lateral flow 'dipstick' read-out is employed to confirm cases of melioidosis. To assess the efficacy of the test, the team collected clinical samples from 114 patients with melioidosis and 216 patients without the disease at Sunpasitthiprasong Hospital, a hospital in northeast Thailand where melioidosis is endemic. The CRISPR-BP34 test was then applied to these samples. The new test showed enhanced sensitivity at 93 per cent, compared to 66.7 per cent in bacterial culture methods. It also delivered results in less than four hours for urine, pus, and sputum samples, and within one day for blood samples. This is a significant improvement over the current bacterial culture diagnostic method, which typically takes three to four days. This new rapid diagnostic test will enable health professionals to prescribe the correct antibiotics faster, meaning fewer patients will die while waiting for a diagnosis. While saving precious time, the new test will also save resources and money, with fewer unnecessary antibiotics prescribed and less time for patients in hospital. In next steps for the team, they are currently designing randomised clinical trials to show the effectiveness of these tests in hospital settings. Plus, members of the team will begin investigating the role of human genetics in susceptibility and immune response to melioidosis infection. Dr ClaireChewapreecha, co-lead author at the Mahidol-Oxford Tropical Medicine Research Unit (MORU), Thailand, and Wellcome Sanger Institute International Fellow, said: "Working in rural Thailand has many limitations. But we have shown that limitations breed innovation, and what succeeds here can succeed anywhere. I am so proud of the team behind this new, robust rapid diagnostic test for melioidosis, and hope that it can potentially be used anywhere in the world to get the right treatments to patients faster, ultimately saving lives." Dr Somsakul Wongpalee, co-lead author at Chiang Mai University, Thailand, said: "We carefully designed the rapid diagnostic test based on CRISPR-BP34, with a robust algorithm, and tested its performance in vitro. We are thrilled that the CRISPR-BP34 test demonstrates outstanding diagnostic efficacy when tested on clinical samples, showcasing its potential to significantly impact patient outcomes and potentially save lives in the near future." Professor Nick Thomson, senior author and Head of Parasites and Microbes at the Wellcome Sanger Institute, said: "This research is a testament to international collaboration and how the application of genomics at scale leads to clinical intervention. Using a genetic target mined from a bank of thousands of bacterial genomes, the team was able to produce an incredibly sensitive test that is specific to the bacterium behind melioidosis. I look forward to seeing the clinical impacts of this research." Professor Nick Day, senior author and Director of the Mahidol-Oxford Tropical Medicine Research Unit (MORU), Thailand, and the Wellcome Trust Thailand Asia and Africa Programme, said: "Melioidosis has been neglected despite its high mortality rate and high incidence in many parts of Asia. Early diagnosis is essential so that the specific treatment required can be started as soon as possible. The new rapid diagnostic tool developed through this collaboration has the potential to be a game-changer."

FRIDAY, March 31, 2023 -- Three weeks of oral azithromycin seems to be equivalent to six weeks of doxycycline for treatment of severe meibomian gland dysfunction (MGD), according to a study published online March 23 in JAMA Ophthalmology . Phit Upaphong, M.D., from Chiang Mai University in Thailand, and colleagues conducted a randomized trial involving patients with moderate-to-severe MGD who were randomly assigned to receive oral azithromycin (1 g once per week for three weeks) or oral doxycycline (200 mg daily for six weeks). Overall, 137 eyes from 137 patients were randomly assigned to the azithromycin and doxycycline groups (68 and 69 eyes, respectively). The researchers found that the adjusted mean between-group difference of total MGD scores was −0.33 and 0.13 at weeks 6 and 8, respectively. At six and eight weeks, the adjusted mean between-group difference in Ocular Surface Disease Index score was −1.20 and −1.59, respectively. Patients treated with azithromycin had fewer gastrointestinal adverse effects (4.4 versus 15.9 percent). "The reduced dosing of azithromycin supports its use as an alternative to doxycycline for at least six weeks," the authors write. "However, longer-term follow-up in each group would be needed to determine if these outcomes persist for this chronic condition." Abstract/Full Text (subscription or payment may be required) Editorial (subscription or payment may be required) Posted March 2023